Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The debt to equity ratio is 0.00 as of the fiscal period ended Tuesday, June 30, 2026.
Reported quarterly debt to equity ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00.
DEBT TO EQUITY RATIO
0.00
DEBT TO EQUITY RATIO AVG TTM
0.00
DEBT TO EQUITY RATIO AVG 3Y
0.00
DEBT TO EQUITY RATIO AVG 5Y
0.00
DEBT TO EQUITY RATIO AVG 10Y
N/A
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.11
median of 687 covered companies
CURRENT VS SECTOR MEDIAN
-100.00%
vs the sector median at left
Nuvectis Pharma, Inc.
Market Cap
$545.19M
Debt to Equity Ratio
0.00
TTM Avg
0.00
3Y Avg
0.00
5Y Avg
0.00
Market Cap
$550.22M
Debt to Equity Ratio
0.28
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$541.20M
Debt to Equity Ratio
0.00
TTM Avg
0.01
3Y Avg
0.01
5Y Avg
0.05
Market Cap
$538.80M
Debt to Equity Ratio
N/A
TTM Avg
0.76
3Y Avg
0.54
5Y Avg
0.54
Market Cap
$538.18M
Debt to Equity Ratio
0.02
TTM Avg
0.01
3Y Avg
0.23
5Y Avg
0.43
Market Cap
$560.00M
Debt to Equity Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$527.70M
Debt to Equity Ratio
0.00
TTM Avg
0.04
3Y Avg
0.02
5Y Avg
0.02
Market Cap
$562.76M
Debt to Equity Ratio
0.02
TTM Avg
0.04
3Y Avg
0.04
5Y Avg
0.04
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Nuvectis Pharma, Inc. (NVCT) | $545.19M | 0.00 | 0.00 | 0.00 | 0.00 |
| BlossomHill Therapeutics, Inc. (BLSM)vs › | $550.22M | 0.28 | N/A | N/A | N/A |
| Aclaris Therapeutics, Inc. (ACRS)vs › | $541.20M | 0.00 | 0.01 | 0.01 | 0.05 |
| Phathom Pharmaceuticals, Inc. (PHAT)vs › | $538.80M | N/A | 0.76 | 0.54 | 0.54 |
| Delcath Systems, Inc. (DCTH)vs › | $538.18M | 0.02 | 0.01 | 0.23 | 0.43 |
| ProKidney Corp. (PROK)vs › | $534.64M | N/A | 0.11 | 0.09 | 0.09 |
| MiniMed Group, Inc. (MMEDV)vs › | $560.00M | N/A | N/A | N/A | N/A |
| Immix Biopharma, Inc. (IMMX)vs › | $527.70M | 0.00 | 0.04 | 0.02 | 0.02 |
| CytomX Therapeutics, Inc. (CTMX)vs › | $562.76M | 0.02 | 0.04 | 0.04 | 0.04 |
| CorMedix Inc. (CRMD)vs › | $565.25M | 0.31 | 0.19 | 0.10 | 0.07 |
Debt/Equity
0.00
Current Ratio
1.68
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2026-06-30 | 0.00 |
| 2026-03-31 | 0.00 |
| 2025-12-31 | 0.00 |
| 2025-09-30 | 0.00 |
| 2025-06-30 | 0.00 |
| 2025-03-31 | 0.00 |
| 2024-12-31 | 0.00 |
| 2024-09-30 | 0.00 |
| 2024-06-30 | 0.00 |
| 2024-03-31 | 0.00 |
| 2023-12-31 | 0.00 |
| 2023-09-30 | 0.00 |
| 2023-06-30 | 0.00 |
| 2023-03-31 | 0.00 |
| 2022-12-31 | 0.00 |
| 2022-09-30 | 0.00 |
| 2022-06-30 | 0.00 |
| 2022-03-31 | 0.00 |
| 2021-12-31 | 0.00 |
| 2021-09-30 | 0.00 |
| 2021-06-30 | 0.00 |
| 2021-03-31 | 0.00 |
